



()

MD

MD

*

-()

// :

// :

IL2

()

(/)

(% /)

/)

(% /)

/

IL2

IL2


- : - : -

()

*

E-mail: fatemeh_nazemian@yahoo.ca

¹ Daclizumab



()

(.)

II

(.)

PRA ()

(.)

Archive of SID

α

IgG1

IL2

(IL2) 2

T

(α , β , γ)

α

T cell


PRA

()

IL2

⁴ PRA: panel Reactive antibodies
⁵ ALS: Anty Lymphocyte

² Delay graft function
³ Cadaver



/ /)

(

()

$p < /$


/ /)

$(p > /$


/ +/- /

/ +/- /

PRA



p value			
$p > /$	/ +/- /	/ +/- /	
$p > /$	/	/	(M/F)
$p > /$	/ +/- /	/ +/- /	PRA
$p > /$	/ +/- /	/ +/- /	
$p > /$	/	/	
$p > /$			
$p > /$			
$p > /$			
$p > /$			



()

/

()

()

IL2

()

()

()

(% /)

()

(% /)

() IL2

()

/ /)

() (

IL2

()

/ /)

(p= /

IL2

β

β

()

⁸ Morris

⁹ Offner

¹⁰ American transplant

¹¹ Chapman

¹² Ponticeli

⁶ Lawen

⁷ Ekberg, Kahan, Lawen

References:

- 1- Griva K, Thompson D, Javaseña D et al. Cognitive functioning pre- to post-kidney transplantation, a prospective study. **Nephrol Dial Transplant** 2006 Jul 22.
- 2 - Gulanikar AC, MacDonal AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. **Transplantation** 1992; 53: 323.
- 3- Mckay DB, et al. Clinical aspect of renal transplantation. In: Brenner BM. **The Kidney**. 7th W.B.Saunders Company; 2004: 2558-2566.
- 4- Boggi U, Danesi R, Vistoli F, et al. A benefit-risk assessment of basiliximab in renal transplantation. **Drug Saf** 2004; 27(2):91-106.
- 5- Lorbera, M, Fastenaub, J, Wilsonc D, et al. A prospective economic evaluation of basiliximab (Simulect®) therapy following renal transplantation. **Clin Transplantation** 2000; 14: 479 – 485.
- 6- Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. **Am J Transplant** 2002 Jul;2(6):568-73.
- 7- Knight R, Burrows L, Bodian C, et al. The influence of acute rejection on long-term renal allograft survival: A comparison of living and cadaveric donor transplantation. **Transplantation** 2001, Jul 15; 72 (1): 69-76.
- 8- Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. **Transplantation** 1996; 62: 1235.
- 9- Meier-Kriesche H U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. **Am J Transplant** 2004; 4: 378.
- 10- Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. **Br Med J** 2003; 326–789.
- 11- Adu N, Cockwell P, Ives N J, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. **BMJ** 2003; 326:789.
- 12- Lawen, J, Davies E, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. **Transplantation** 2003 Jun 15; 75 (1): 37 – 43.
- 13- Ekberg H, Backman L, Tufveson G, et al. Zenapax (Daclizumab) Reduces the Incidence of Acute Rejection Episodes and Improves Patient Survival Following Renal Transplantation. **Transplantation Proceedings**, 1999; 31: 267–268.
- 14- Kahan B, Rajagopalan PR, Hall M, et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with Basiliximab, a chimeric anti Interleukin-2 receptor monoclonal antibodies. **Transplantation** 1999; Jun 27; 67 (2): 276 – 284.
- 15- Morris JA, Hanson JE, Steffen BJ, et al. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. **Clin Transplant** 2005 Jun; 19(3):340-5.
- 16- Julio Pascual, Roberto Marcén and Joaquín Ortuño. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. **Nephrol Dial Transplant** 2001; 16: 1756-1760.

- 17- Offner G, Broyer B, Niaudet P. A multicenter, open-label, Pharmacokinetics/ Pharmacodynamics safety, and tolerability study of Basiliximab in pediatric de novo renal transplant recipients. **Transplantation** 2002 Oct 15; 74(2): 961-966.
- 18- Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. **BioDrugs** 2005; 19 (1):39-46.
- 19- Meier K, Schold J, Titte R, et al. Long term risk of antibody induction therapy in kidney transplantation. **Am J Transplant** 2004; 4 (8): 264 (Abstract #386).
- 20- Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. **Transplantation** 2001 Oct 15; 72(7):1261-7.
- 21- Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. **Drugs** 2003; 63(24):2803-35.

Archive of SID